Gilead Sciences GILD NASDAQ:GILD

Biotech Volatile Stocks: DARA Biosciences Inc (NASDAQ:DARA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Prosensa Holding NV (NASDAQ:RNA), CytRx Corporation (NASDAQ:CYTR)

DARA Biosciences Inc (NASDAQ:DARA) on May 15 announced its support for Neuropathy Awareness Week which is being observed during the week of May 12, 2014 and sponsored in the U.S. by The Neuropathy Association ( DARA Biosciences Inc (NASDAQ:DARA) stock performance was -26.61% in last session and finished the day at $1.60. Traded volume was 4.15million shares in the last session and the average volume of the stock remained 501.39K shares. The beta of the stock remained 1.63. DARA Biosciences Inc (NASDAQ:DARA) insider ownership is 0.90%.

Analysts at Roth Capital assumed coverage on shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating and a $28.00 price target on the stock. Roth Capital’s price objective suggests a potential upside of 224.07% from the stock’s previous close. Concert Pharmaceuticals Inc (NASDAQ:CNCE) rose 1.97 percent to $8.81 Thursday on volume of 115,127.00million shares. The intra-day range of the stock was $7.76 to $9.06. Concert Pharmaceuticals Inc (NASDAQ:CNCE) has a market capitalization of $157.70million.

Prosensa Holding N.V. (NASDAQ:RNA) announced that Luc Dochez, Chief Business Officer, will present a corporate overview at the Jefferies 2014 Global Healthcare Conference in New York, NY. The presentation is scheduled for Wednesday, June 4, at 1:30pm EDT. A live webcast of the presentation can be accessed through the Investors & Media section of the Prosensa corporate website at and will be archived for 90 days. Prosensa Holding NV (NASDAQ:RNA)’s stock on May 29, 2014 reported a increase of 11.67% to the closing price of $9.95. Its fifty two weeks range is $3.43 -$34.55. The total market capitalization recorded $357.95million. The overall volume in the last trading session was 967,517.00million shares. In its share capital, RNA has 35.90million outstanding shares.

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). On Thursday, shares of CytRx Corporation (NASDAQ:CYTR) dropped -5.33% to close the day at $3.91. Company return on investment (ROI) is -257.90% and its monthly performance is recorded as 24.52%. CytRx Corporation (NASDAQ:CYTR) quarterly revenue growth is -36.63%.